Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency
PLOS One · 20.07.2026 · 21 (7) · e0348959
DOI: 10.1371/journal.pone.0348959 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 20.07.2026. Verfasst von Jade Jansen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Meibergdreef, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Lipid A, HIV-1, Virus Latency, Adjuvants, Immunologic. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health~Holland, zonmw, Aidsfonds.
Abstract (Originalsprache)
Monophosphoryl lipid A (MPLA) and the saponin-MPLA nanoparticle adjuvant (SMNP) are known immunostimulants used as adjuvants in vaccines to boost immunity. These adjuvants are under investigation for use in prophylactic and therapeutic HIV-1 vaccines. However, their effects in ART-treated people with HIV-1 (PWH) remain unclear, as chronic immune activation may reduce responses and potentially reactivate latent virus reservoirs. Here we observed that both adjuvants, MPLA and SMNP, triggered TLR4‑dependent cytokine production in monocyte-derived dendritic cells (DCs), but SMNP elicited a stronger response than MPLA based on costimulatory receptor expression and cytokine production. Cytokines produced by adjuvant stimulated dendritic cells were able to induce HIV-1 transcription in a J-Lat cell model. Notably, SMNP, but not MPLA, also induced a cytokine response in PBMC from PWH, albeit lower as compared to in healthy donor PBMC. Importantly, SMNP substantially reduced the size of the inducible HIV‑1 reservoir in PWH ex vivo . The effect on the viral reservoir was likely caused by the cytokine production induced by SMNP, as supernatants from SMNP stimulated DCs showed a similar viral reservoir reduction. Our findings demonstrate that TLR4-targeted adjuvants, especially SMNP, can effectively induce immune activation, supporting their potential use in therapeutic vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Meibergdreef, Amsterdam, The Netherlands.
- Amsterdam institute for infectious diseases and immunology, Amsterdam, The Netherlands.
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Meibergdreef, Amsterdam, The Netherlands.
- Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, United States of America.
- Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef, Amsterdam, The Netherlands.
ORCID-Profile: Neeltje A Kootstra
Förderung
- Health~Holland
- zonmw
- Aidsfonds
- Aids Fonds
Zitieren
APA
Jansen, J., Vlaming, K. E., Helgers, L. C., Schumacher, E., Kaptein, T. M., Sanders, R. W., de Bree, G. J., Geijtenbeek, T. B. H., & Kootstra, N. A. (2026). Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency. PLOS One, 21(7), e0348959. https://doi.org/10.1371/journal.pone.0348959
Vancouver
Jansen J, Vlaming KE, Helgers LC, Schumacher E, Kaptein TM, Sanders RW, et al. Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency. PLOS One. 2026;21(7):e0348959. doi:10.1371/journal.pone.0348959
BibTeX
@article{Jansen2026,
author = {Jansen, Jade and Vlaming, Killian E and Helgers, Leanne C and Schumacher, Eva and Kaptein, Tanja M and Sanders, Rogier W and de Bree, Godelieve J and Geijtenbeek, Teunis B H and Kootstra, Neeltje A},
title = {Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0348959},
doi = {10.1371/journal.pone.0348959}
}
EUVIMED